ACH-3102 and Sovaldi Have 100% Hepatitis C Cure Rate in 6 Weeks

Six weeks of Achillion’s ACH-3102 and Gilead Sciences’ Sovaldi (sofosbuvir) cured 100 percent of a small trial of people with genotype 1 of hepatitis C virus (HCV). The Phase II study of NS5A inhibitor ACH-3102 and the analog polymerase inhibitor Sovaldi included 12 people with genotype 1: seven with genotype 1a and five with genotype 1b. Read more:


You may also like...